Infections pose a significant threat to global health, with a substantial economic impact on healthcare systems. Timely and accurate diagnosis is crucial for determining the best treatment, preventing the inappropriate use of antibiotics, and averting the risk of serious complications.

Among the most common infections are urinary tract infections (UTIs), which, if not detected promptly, can have severe consequences, especially for vulnerable groups such as the elderly or pregnant women. Indeed, since 1990, deaths related to UTIs have more than doubled¹, and their economic impact on the US healthcare system exceeds $7 billion.

A solution to these problems comes from GeneSys Bio, a company formed by a team of experts both in the diagnostic field and in the development of medical devices, with more than 10 patents and 30 scientific publications to their name.

Specifically, the startup has developed GeneSys: a portable and easy-to-use device that allows for rapid and accurate diagnostic tests, anywhere and at any time.

Thanks to its AI-enhanced PCR technology, combined with the use of ready-to-use reagents that do not require a cold chain, this solution aims to reduce the costs and time of diagnosis, thus avoiding the inappropriate use of antibiotics and consequently improving patient well-being.

GeneSys is a versatile and scalable platform that can be adapted to various applications. For this reason, the startup plans to develop new kits for diagnosing an increasingly broad range of pathogens, thereby making a significant step forward in the fight against infections and in promoting global health.

From January 2024, GeneSys Bio has been part of the Bio4Dreams network.

Bibliography

¹ Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019, 2021.